Axsome Therapeutics, Inc. $AXSM Shares Purchased by UBS Group AG

UBS Group AG boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 67.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 355,318 shares of the company’s stock after acquiring an additional 142,867 shares during the quarter. UBS Group AG’s holdings in Axsome Therapeutics were worth $64,895,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXSM. Versant Capital Management Inc boosted its holdings in Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after acquiring an additional 203 shares during the last quarter. First Horizon Corp acquired a new position in Axsome Therapeutics in the third quarter valued at $34,000. Optiver Holding B.V. boosted its holdings in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in Axsome Therapeutics in the third quarter valued at $38,000. Finally, Advisory Services Network LLC acquired a new position in shares of Axsome Therapeutics during the third quarter worth about $40,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 8.5%

NASDAQ:AXSM opened at $224.03 on Tuesday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.48 and a current ratio of 1.55. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $234.29. The business’s 50-day simple moving average is $170.95 and its 200 day simple moving average is $162.68. The stock has a market cap of $11.52 billion, a price-to-earnings ratio of -60.71 and a beta of 0.59.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The company’s revenue for the quarter was up 57.4% compared to the same quarter last year. As a group, sell-side analysts predict that Axsome Therapeutics, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Mark Coleman sold 25,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the transaction, the director owned 47,140 shares in the company, valued at approximately $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Mark L. Jacobson sold 35,378 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 67,878 shares of company stock worth $11,122,891. 22.30% of the stock is currently owned by corporate insiders.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q1 revenue beat and strong year-over-year growth: Net product revenue was $191.2M (vs. $191.1M consensus) and up ~57% year-over-year, driven by Auvelity ($153.2M) and Sunosi ($33.9M). This supports continued commercial momentum across core products. Read More.
• Positive Sentiment: Regulatory and pipeline progress: Auvelity received an approval for agitation associated with dementia due to Alzheimer’s disease, and Axsome submitted an NDA for AXS‑12 (cataplexy). The company also added AXS‑20 (PDE10A inhibitor) to the pipeline—these expand addressable markets and future revenue potential. Read More.
• Positive Sentiment: Analyst/broker tone and investor engagement: Broker consensus is a “Moderate Buy,” and management will be participating in multiple investor conferences in May (BofA, fireside chat, etc.), which can boost visibility and help reprice expectations. Read More. Read More.
• Neutral Sentiment: Company events and disclosures: Management hosted a conference call and published a slide deck and transcript; analysts will parse details on unit trends and cost trajectory during conference appearances. Read More.
• Negative Sentiment: EPS miss and continued losses: Reported EPS was a loss of $1.26 vs. consensus -$0.85 (miss), and the company remains unprofitable with negative margins and ROE metrics—this leaves valuation sensitive to execution. Read More.
• Negative Sentiment: Mixed product trends flagged by analysts: Despite strong YoY growth, some analysts note sequential declines in Auvelity and Sunosi sales and call management’s peak revenue targets ambitious, which could limit upside if sustained. Read More.

Analyst Ratings Changes

A number of research analysts have commented on AXSM shares. Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a research note on Monday. TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research note on Friday. Needham & Company LLC boosted their price objective on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday. Guggenheim restated a “buy” rating and set a $260.00 price objective on shares of Axsome Therapeutics in a research note on Monday. Finally, Leerink Partners boosted their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $235.79.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.